High long-term retention rates of Secukinumab in psoriatic arthritis and ankylosing spondylitis: a 3-year interim analysis from the observational, prospective SERENA study, in Greek patients

SERENA is a recently completed, non-interventional, multinational, 5-year study evaluating retention, effectiveness, patient-reported outcomes and safety of secukinumab in patients with moderate-to-severe psoriasis, active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS) treated in real-world settings. Three-year interim data from PsA and AS patients treated in Greek centres are presented herein. PsA and AS adults receiving secukinumab per the approved label for ≥ 16 weeks were included. Overall, 214 PsA and 81 AS eligible patients were enrolled, with mean age of 53.0 and 48.2 years and mean disease duration of 7.5 and 9.1 years, respectively. Of PsA and AS patients, 73.4% and 56.8% were bio-experienced, respectively. Secukinumab retention rates at 1, 2, and 3 years post-enrolment were 87.1%, 76.9%, and 74.0% in PsA and 89.9%, 80.5%, and 77.3% in AS patients, respectively. Main reasons for drug discontinuation were lack of effectiveness (37.1%) and adverse event (AE; 27.1%). The safety set (patients with at least 1 secukinumab dose after signing the informed consent) included 218 PsA and 81 AS patients, of whom 13.3% and 13.6% experienced secukinumab-related AEs, respectively. One malignancy was reported. No candida infections, major adverse cardiovascular events, inflammatory bowel disease or uveitis were reported. In conclusion, similarly high persistence to secukinumab was observed for both PsA and AS after 3 years of observation, with a favourable safety profile.